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Summary.-The results of radiation therapy in 212 patients with stages I and II
Hodgkin's disease treated between 1963 and 1973 show that approximately 60%
remain disease-free following treatment. Multiple node involvement in stage II,
particularly associated with infraclavicular node disease, is identified as a group
where the relapse rate is high. This presentation is associated particularly with NS.
In a group of78 patients treated with radiotherapy following staging laparotomy
and splenectomy approximately 80% remain in complete remission. The pre-
liminary results of treatment in PS IIIa patients are substantially the same as those
for PS I and II; the results of treatment for NS and MC disease are similar. The
significance of involvement of the spleen is discussed. Although it is probable that
Hodgkin's disease spreads to the spleenthrough the blood stream it is suggested that
splenic involvement does not necessarily indicate that the involvement of other
extralymphatic structures such as liver and marrow has occurred. However, when
the nodes in the porta hepatis are involved splenic Hodgkin's disease may well be
associated with an increased risk of occult hepatic infiltration.
HODGKIN'S disease, untreated or
inadequately treated, carries a grave
prognosis. However, important advances
in the investigation and treatment of this
condition have occurred over the past
10-15 years and the major issues of
pathological classification and clinical and
pathological staging (Carbone et al., 1972)*
have been discussed and clarified at
several international meetings held
during this period (Paris, 1966; Rye, 1966;
Stanford, 1973).
Results of previous treatment in this
hospital have been reported in several
publications (Smithers, 1969; Smithers
and Peckham, 1973; Peckham, 1973 b).
Experience in the biology, investigation
and management of Hodgkin's disease at
the Royal Marsden Hospital and Stanford
University has been presented separately
in monographs published in 1973 (Kaplan,
1972; Smithers, 1973).
Laparotomy and splenectomy was
first employed at this centre in 1969 and
experience has amply demonstrated that
failure of treatment based upon a purely
clinical assessment ofthe extent ofdisease
may be due in large part to the presence of
undetected occult abdominal tumour,
particularly involvement of the spleen
(Glatstein et al., 1969; Gazet, 1973).
The current radiotherapeutic manage-
ment of Hodgkin's disease has developed
from the concepts described by Gilbert
(1939) and developed by Peters (1950).
An important feature of this approach is
the concept of treating apparently un-
involved nodal areas adjacent to clinically
obvious disease. The present form of
treatment was developed by Kaplan
(1962) who demonstrated that irradiation
of the axial lymphatic system (total nodal
irradiation) was a practical procedure
(Kaplan and Rosenberg, 1966). An
* Staging according to the Ann Arbor system (Carbone et al., 1972) in stage II the number ofnodal areas
involved is indicated as follows: 11(2) 2 nodal areas, II(3) 3 nodal areas, II(,+) more than 3 nodal areas.M. J. PECKHAM ET AL.
alternative approach to therapy has been
advocated by Johnson et al. (1970) who,
rather than performing a staging laparo-
tomy, electively irradiate the spleen in
clinically staged patients.
It is not proposed in this communi-
cation to review previous experience but
rather to present recent results of treat-
ment with radical radiotherapy in patients
staged by clinical procedures and more
recently by pathological staging tech-
niques. Those groups ofpatients most at
risk from relapse are identified and our
preliminary experience of treatment in
patients who have undergone splenectomy
as part of their initial assessment is
presented.
PATIENTS AND METHODS
Treatment groups.-It has been our policy
to reserve chemotherapy for stage IlIb and IV
patients and to irradiate patients with stages
I (a and b), II (a and b) and Illa disease.
This policy was adopted in order to provide a
better appreciation ofthe causes oftreatment
failure and in order to identify patients in
whom a combined approach would be more
likely to succeed. In addition, we have been
anxious to avoid overtreating patients by
combining irradiation and combination
chemotherapy until we were in a position to
identify those groups with a high risk of
relapse from either treatment used alone.
Staging procedures.-(Throughout this
article clinical stage is abbreviated to CS and
pathological stage to PS.) Clinical staging
includes lymphography, intravenous pyelo-
gram and chest x-ray, liver and spleen scans,
liver functiontests and bone marrow sampling
(initially aspirate but since 1969 trephine, or
open iliac crest biopsy). In some cases
percutaneous needle biopsy of the liver was
also performed. Over the past 5 years
staging laparotomy has been carried out in
the majority of patients at presentation.
The latter procedure is now routinely carried
out in clinically staged (CS) I (a and b), II (a
and b) patients and stage Illa patients.
More recently, CS IlIb patients have been
pathologically staged (PS) but this was not
the case during the time covered by the
present analysis. In patients presenting
with infradiaphragmatic disease, the left
scalene nodes are sampled routinely.
Treatment methods.-These have been
described in a previous publication (Peckham,
1973b) and will be mentioned only briefly.
Between 1963 and 1969 patients with
supradiaphragmatic stage I and II disease
received irradiation by the mantle technique
which involves the en-bloc irradiation of the
mediastinal, axillary and cervical nodal areas
using large anterior and posterior fields, the
majority of patients being treated with a
linear accelerator. During this time, CS Illa
patients who did not have splenic enlarge-
ment either clinically or on scanning and in
whom systemic symptoms were absent
received total nodal irradiation in which the
mantle treatment was followed after an
interval of one month by irradiation of the
para-aortic, iliac and inguinal nodes (inverted
" Y " field). The spleen was not irradiated
or removed in this group of patients.
Patients with infradiaphragmatic stage I and
II disease were treated with the inverted
" Y " technique. After the introduction of
laparotomy, PS I and II patients with
supradiaphragmatic disease were treated
initially with a mantle field but when it
became evident that a small proportion were
relapsing in the para-aortic region, even when
both lymphogram and laparotomy were
negative, it was decided to irradiate this
region. This is done with a separate field
extending down to L5/S1 interspace and
treatment is started about one month after
completion of supradiaphragmatic irradi-
ation. PS Illa patients receive total nodal
irradiation which includes the splenic axis if
the spleen was involved by tumour.
The survival rates were computed by the
actuarial method incorporating a correction
for expected deaths due to causes other than
Hodgkin's disease. The correction was made
using national mortality statistics by the
method of Berkson and Gage (1950).
Patients.-Between 1963 and 1973, 238
stage I and II patients were treated at the
Royal Marsden Hospital. Patients who were
previously treated or who were lost to follow-
up have been excluded leaving a total of 212
for analysis. Since the introduction of
laparotomy, 78 PS I (a and b), II (a and b)
and IlIa patients are available for analysis.
The survival ofPS I and II patients has been
compared with the survival of the entire
group (CS and PS) of patients treated be-
tween 1963 and 1973. The results of
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treatment of PS patients have not been
compared with CS patients since initially
many CS Ia and Ila patients did not undergo
laparotomy, which was restricted to those
patients considered particularly at risk.
Patients who as a result of the findings of
staging laparotomy wtere treated wnith chemo-
therapy rather than radiotherapy. Any
observed improvement in the results of
radiotherapy might be attributable in the
splenectomy group to the re-allocation of a
proportion of patients to the chemotherapy
group. The only ways in which this could
occur were the re-staging of CS I and Ilb as
PS Illb or ofany CS I and II or Illa patients
as PS stage IV. The latter transition was
exceptional. During the period 1970 to 1973
21 CS lb and IIb patients were seen and their
final staging is summarized below:
Cs
Total (No
CS Ib, IIb laparotomy)
21 5
PS Ib, Ilb PS IlIb
10 6
Thus, there are only 6 patients in this
group who before 1970 would have received
radiotherapy but who were treated instead
with radiotherapy plus chemotherapy or
combination chemotherapy alone as a result
of the laparotomy findings.
Histological yrading. (Throughout this
article lymphocytic predominance is abbrevi-
ated to LP, nodular sclerosis to NS, mixed
cellularity to MC and lymphocytic depletion
to LD.) Histological grading has been
carried out according to the modified Lukes
classification (Lukes et al., 1966) into the
following 4 categories: lymphocytic pre-
dominance (LP), nodular sclerosis (NS),
mixed cellularity (MC) and lymplhocytic
depletion (LD). Histological material for
each patient has been reviewed at the Royal
Marsden Hospital in most cases by Dr I. M. E.
Hamlin.
RESULTS
Table I summarizes the results of
treatment in stage I and II patients
treated between 1963 and 1973. Of this
entire group of 212 patients, 164 were
clinically staged and 48 pathologically
staged and, as mentioned above, those
patients undergoing laparotomy initially
were selected in the sense that they were
TABLE I. Radiotherapy for Stage I & I*
Hodgkin's Disease (The Royal Marsden
Hospital, 1963-73)
Mlales
Females
Total
* Majority clinical
No. Disease-free
of since
patients irradiation
118 67 (56 * 8%)
94 66 (70O2 %)
212 133 (62 7 %)
Ily staged.
considered to be particularly at risk of
harbouringoccult intra-abdominal disease.
Approximately 60% of the whole group
remain in complete remission after radical
radiotherapy with females faring better
than males (70 2% compared with
56- 8%).
Table II shows the results in terms of
histological grade, a diminishing disease-
free survival rate is seen from LP, NS to
MC, the differences between LP and MC
being the most striking.
TABLE II. Hodgkin's Disease: Stages I &
II* (The Royal Marsden Hospital
1963-73 inclusive)
Complete remission
Histology since irradiation Total
LP 23 (82%) 28
NS 87 (62-1%) 140
MC 23 (52%) 44
133 (62- 7%) 212
* The majority of these patients were clinically
staged.
Lymphocytic depletion results are
summarized in Table III. This is a small
group consisting of only 10 cases pre-
senting with stage I, II and Illa disease.
TABLE III. Lymnphocytic Depletion
Hodgkin'sDisease,LymphographicStages
I, II & III (The Royal Marsden Hos-
pital, 1963-73)
Stage
Ia
IIa
IIb
Illa
Total
2
1
3
4
Alive
0
0
1
1
Dead
2
1
2
3
Survival time
(months)
Alive Dead
9, 33
15
67 14, 33
42 9,8,21
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TABLE IV.-Relapse Pattern in Stages I & II Hodgkin's Disease (LP, NS and MC)
treated with Radiotherapy (The Royal Marsden Hospital 1963-73)
Abdominal extension to
L. neck in case ofinfra-
diaphragmatic
presentation
In CS In PS
Total patients patients
(A) Lymphocytic Male
predominance Female
Total
(B) Nodular Male
sclerosist Female
Total
(C) Mixed Male
cellularity Female
Total
5
0
5
31
22
53
16
5
21
Abdominal
extension
and loco-
marginal
relapse
4
4
13
5
18
13*
2
15
4
2
6
1
1
Loco-
marginal
relapse
1
1
6
12
18
2
2
Uncontrolled
aggressive
disease
6
2
8
1
2
1
3
1
1
2
t Of53 relapses, 17 developed lung involvement, 5 infraclavicular node extension and 3 bone involvement.
* 3 infradiaphragmatic presentations extending to L. cervical nodes and in one case, L. axillary node.
Despite recent advances the prognosis for
LD remains poor and 8 of 10 patients in
this series are dead.
The causes of treatment failure in
stages I and II (excluding LD) are
summarized in Table IV. Of the NS
patients abdominal extension was the
cause of disease relapse in 18 of the CS
patients but this has so far only been
encountered in 3 of the PS group It is
important to note that 18 patients had
either local recurrence or marginal
extension and 8 were considered to have
aggressive disease which was not con-
trolled by radiation therapy. In this
latter group, local or marginal relapse was
an important cause of treatment failure
and in 4 out of 8 cases multiple nodal
areas ofinvolvement were present initially.
In 4 of the 5 relapses in patients with
LP this was due to abdominal extension.
Abdominal extension is particularly
important in MC disease, accounting for 15
of the 21 relapses which have occurred.
However, only 2 abdominal relapses have
occurred in the PS group. There is thus a
marked difference in the relapse pattern of
MC compared with NS. In the latter
group loco-marginal relapse is a relatively
common cause of treatment failure
whereas this is uncommon in MC. In LD
3 out of 5 patients with relapse have had
uncontrolled locally aggressive disease.
The time interval between treatment
and relapse in stages I and II patients is
shown in Fig. 1. 54% of relapses
occurred within 12 months and 85%
within 24 months of radiation therapy
with few occurring after 36 months. In
68% of patients with loco-marginal recur-
rence this became apparent within 12
months of treatment. There is a sug-
gestion, as might be expected, that local
relapse appears sooner than abdominal
relapse. Fig. 2 summarizes the disease-
free rates in stages I and II disease in
histogram form and shows that in those
patients with multiple nodal areas
involved (Ila(3+)) the relapse rate is high.
Fortunately, the most common presen-
tation within stage II is associated with
involvement of 2 or 3 nodal areas. Fig. 3
shows the disease-free survival of stages
I and II patients isolating those patients
with more than 3 nodal areas involved.
This group is frequently associated with
infraclavicular disease and Table V
summarizes the pretreatment disease
extent in 10 patients with infraclavicular
disease and their subsequent course. It
is apparent that even in PS patients with
considerable attention being paid to
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The Royal Marsden Hospital (1963- 74)
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treatment planning, the relapse rate in
this group remains high. Of 6 PS
patients with infraclavicular nodal
involvement detected at presentation, 1
was given combination chemotherapy
electively after irradiation, 2 remain in
complete remission and 3 have relapsed, 2
with local recurrence or loco-marginal
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TABLE V.-Stage II Nodular Sclerosing Hodgkin's Disease with Infraclavicular Nodal
Involvement (The Royal Marsden Hospital)
Total
1
1
2
4
2
Loco-marginal
recurrence
Number Local + abdominal Marginal
relapsing recurrence extension relapse
1 1
1 1
2
3
0
1
2
Extension to
abdomen or
distant extra-
lymphatic
spread
1
1
2
Disease-
free
since
radio-
therapy
1
2
3 3
1
10 7 1
TABLE VI.-Radiotherapyfor PS I & II Hodgkin's Disease (The Royal
Marsden Hospital, 1969-73)
Causes of treatment failure
No. of Complete Extension to opposite Loco-marginal
Stage patients remission side ofdiaphragm recurrence
14 13 1
6(2+3) 18 18
1(3+) 7 2 3 2
)(2+3) 4 2 1 1
)(3+) 5 4 1
48 39
(81 3%)
5
(10.4%)
4
(8.3%)
TABLE VII.-RadiotherapyforPS lIaHodgkin's Disease (The Royal Marsden
Hospital, 1969-73)
Complete
remission
Systemic
symptoms
Marginal
ex,tension
Spleen* since *liver Marginal *liver
Histology status Total irradiation involvement extension involvemE
LP S- 2 2
S+ 1 1
NS S- 6 5 1
S+ 9 7 1
Mc s- 1 1
S+ 11 7 3 1
Total 30 23t (76 7 %) 3 3 1
* - and S+ indicate histological status of spleen.
t 1 died of intercurrent disease at 18 months, no Hodgkin's disease at post mortem examination.
extension. One patient in this group has
died.
The outcome of treatment in PS I and
II patients is summarized in Table VI.
Of the total of 48 patients, 81% remain in
complete remission. Of 9 relapses, 5 have
been due to extension of the disease to
lymph nodes on the opposite side of the
diaphragm and in 4 cases to loco-marginal
extension. The results of 30 PS Illa
patients (Table VII) show that when the
spleen is negative the results of radio-
therapy are good, 8 out of 9 remaining
disease-free. Of 21 patients with splenic
involvement, 6 have relapsed; 4 with MC
and 2 with NS disease. In 3 of these 6
relapses, liver involvement was probable
but not proven. Those patients with
porta hepatis node involvement are
particularly at risk from this point of
view. One patient with splenic Hodgkin's
disease died of intercurrent disease at 18
months with no evidence of recurrent
Hodgkin's disease at autopsy. Between
Stage
CSIIa (3+)
CSIIb (3+)
CSIIe (3+)
PSIIa (3+)
PSIIb (3+)
Total
Dead
I
1
1
Ia
IIa
IIa
lIb
IIb
Toltal
ent
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The Royal Marsden Hospital
RESULTS OF RADIATION THERAPY
FOR HODGKIN'S DISEASE (1963 - 73)
L-
-6.
1-
::
vh
20-
10-
3urvival, stage I & II (1963- 73)
Disease-free survival after radiation
therapy, stage I & II (1963 - 73)
Disease-free survival after radiation
therapy, pathological stage I & II
(1970- 73)
Disease-free survival after radiation
.therapy, pathological stage I, II & IIIa
(1970- 73)
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FIG. 4
1963 and 1969, 22 patients with CS Illa
disease were treated with irradiation and
only 36% remain in complete remission,
compared with 23 out of 30 PS Illa
patients (77%) (one patient died of
intercurrent disease). Finally, Fig. 4
summarizes the overall survival and
disease-free survival of the entire group of
stages I and II patients treated between
1963 and 1973. The projected results for
the 78 patients with PS I, II and Illa
disease suggests a considerable improve-
ment in disease-free survival. This figure
also indicates that the results oftreatment
for stage Illa disease are essentially
similar to that of the stages I and II.
DISCUSSION
The rapid evolution which has occurred
in the management of Hodgkin's disease
as a result of the introduction of several
important investigative and therapeutic
techniques has rendered an appraisal of
treatment results difficult, especially since
most ofthese changes haveoccurredwithin
theshortspaceofonedecade. The majority
of clinical trials which have been under-
taken were carried out before the advent
of staging laparotomy. This latter pro-
cedure has clearly demonstrated that
splenic involvement may be present in
patients with apparently localized supra-
diaphragmatic disease. The proportion
of positive spleens will clearly depend
upon patient selection, in particular upon
the distribution of patients according to
histological subtype. In our own series
approximately 40% of patients submitted
to laparotomy have histological evidence
of involvement of the spleen. From the
outset it has been our policy to treat one
group of patients with radiation therapy
alone (stages I, II and Illa) and another
group, with more advanced disease, with
combination chemotherapy (stages IIIb
and IV). By adopting this policy it was
hoped that bad-risk groups could be
identified as suitable for treatment with
both irradiation and chemotherapy, while
at the time same avoiding the overtreat-
ment of the majority of patients. As
reported in a previous publication
(Peckham, 1973b) about 60% of CS I and
II patients remain disease-free after
radiation therapy and since relapse has
generally occurred within 3 years of
therapy, it is reasonable to suppose that a
substantial proportion of this group may
be considered as cured of their disease.
The time to relapse after irradiation in the
present series shows that in 85% of
patients who relapse this has occurred by
2 years. This is similar to the figure of
82% reported by the Stanford group
(Spittle et al., 1973). An examination of
the causes of treatment failure in CS
patients reveals, as might be expected,
that the subsequent appearance of
abdominal disease was an important
cause of relapse. Thus, in the period
before the introduction of laparotomy,
abdominal extension occurred in no less
than 18 of 21 relapses in patients with MC
disease. Patients with this histological
subtype have an increased chance of
splenic involvement, for example, of 15
n -- I v ~ :-
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CS I presentations with MC disease who
have undergone laparotomy in the past 3
years in this hospital, no less than 11 have
had involved spleens and if the fate of
those patients who were treated in the pre-
laparotomy period and who presented in a
similar way is examined it is not surprising
to find that only 1 of 7 patients remains
disease-free, with 6 relapses occurring in
the abdominal cavity. Thus, in the era
when clinical staging alone was employed
(1963-69) we would expect to see an
important difference between the treat-
ment results in the different histological
subgroups. Certainly LD is associated
with an appalling prognosis with 8 of 10
patients (stages I, II and Illa) having
died ofHodgkin's disease. The difference
in disease-free survival rate between LP
and MC is marked but there is little
difference between NS and MC. These
results suggests that factors other than
undetected, and hence untreated,
abdominal disease may have influenced
the treatment results. It is apparent that
patients with multiple nodal involvement
above the diaphragm have proved difficult
to control with radiotherapy and if the
group with more than 3 nodal areas
involved is considered alone, the disease-
free and overall survival results are seen to
be markedly inferior to the stages I and II
results as a whole. This is particularly
true of NS, where more than 90% of
patients in this small group have relapsed.
These patients often have infraclavicular
node involvement and, as Table V shows,
when this is present the chances ofrelapse
are high. In this group an association of
chemotherapy with radiotherapy is
indicated and we now prefer to precede
irradiation by several courses of combin-
ation chemotherapy, continued until the
patient is in complete remission.
It may be argued that the improve-
ment in treatment results forradiotherapy
in PS patients may be due to the re-
allocation of the more advanced patients
to the chemotherapy group (PS IIlb and
IV) following laparotomy. In our
experience liver involvement in CS I, II
and Illa is rare and the transition of
patients from these stage categories to
stage IV has been exceptionally un-
common. CS lb and Ilbpatientswhoprove
to have abdominal disease and who are
placed in the PS IIlb group would have
been treated with chemotherapy rather
than irradiation. In fact, this occurred in
only 6 patients.
The important question as to whether
therapy based upon the findings of PS
procedures is likely to improve treatment
results depends in large part on whether
involvement of the spleen indicates wide-
spread haematogenous dissemination or
whether Hodgkin's disease of the spleen
still represents tumour localized to the
lymphatic system. The mechanism
whereby Hodgkin's disease spreads to the
spleen is unknown. Halie et al. (1972)
have described the presence of large
circulating cells of indeterminate type in
patients with splenic involvement and
suggested that Hodgkin's disease spreads
to the spleen via the blood stream and that
splenic involvement is an indicator of
disseminated disease. Quantitative cyto-
chemical studies carried out in one of our
patients at presentation and subsequently
in relapse when splenic involvement was
diagnosed, showed a narrower range of
nuclear DNA contents in splenic
Hodgkin's tissue (comparable with the
initial biopsy) compared with the marked
aneuploidy of the para-aortic node
removed at the same time as the spleen
(Peckham, 1973a). This observation is
consistent with the hypothesis that foci of
Hodgkin's disease in the spleen are
established by cells circulating from the
large mass ofnodaltumour. The question
perhaps is not so much whether Hodgkin's
disease spreads to the spleen via the blood
stream but whether this necessarily
indicates metastases to other extralym-
phatic sites, particularly the liver and
the marrow. That "organ-localized"
haematogenous spread can occur in malig-
nant disease is demonstrated by the cure
occasionally effected in testicular teratoma
by the excision of solitary pulmonary
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metastases and in colonic carcinoma by
p)artial hepatectomy for liver metastases.
Ln a recent study ofthe fate of circulating
lymphoma cells in the murine Hodgkin-
like type-B neoplasm, Parks (1974) has
shown that initial uptake of iododeoxuri-
dine labelled tumour cells in the lung,
liver, kidney and spleen was followed by
progressive depletion oftumour cells in all
sites except the spleen, which at autopsy
proved to be the only site where tumour
nodules could be demonstrated.
It has been suggested that involve-
ment of the spleen in Hodgkin's disease is
strongly correlated with hepatic infil-
tration and that some form of systemic
therapy is therefore indicated in patients
with splenic Hodgkin's disease (Kaplan,
1970). On this basis, patients in the
Stanford trials have received either chemo-
therapy in addition to total nodal irradi-
ation or intravenous radioactive colloidal
gold and hepatic irradiation (Kraut,
Kaplan and Bagshaw, 1972; Rosenberg
et al., 1972). On the other hand, the
results reported by Johnson et al. (1970)
who have irradiated the spleen electively
in CS I and II, where it might be expected
that at least one-third of patients would
have had splenic Hodgkin's disease, are
consistent with the conclusion that splenic
Hodgkin's disease is locally curable and
not therefore invariably associated with
hepatic involvement. On the basis of a
preliminary report, Shipley, Piro and
Hellman (1974) have suggested that
approximately 15% of patients with
splenic involvement have disseminated
extranodal disease, the remainder showing
results comparable with radiotherapy to
patients with Hodgkin's disease localized
to the lymph nodes.
On the basis of our own observations
and those described above, it is suggested
that although spread to the spleen via the
blood stream may occur, such spread may
be localized to the spleen where it is
curable by localized forms oftherapy such
as irradiation or surgery.
It is clearly premature to be able to
sustain this hypothesis with clinical evi-
dence and our preliminary information
suggests that the presence ofporta hepatis
node involvement in association with
involvement of the spleen might well
indicate occult, undetected hepatic
Hodgkin's disease. If, as seems likely,
radical radiotherapy based upon the
accurate disease localization, provided by
clinical and pathological staging tech-
niques does prove to be an advance upon
previous treatment methods, then we
might expect staging and perhaps also
histological grade to become less important
prognostic indicators. The results shown
in Fig. 4 suggest that this is occurring in
that the disease-free survival of patients
has been enhanced considerably by PS
with the results for stage Illa patients
being substantially the same as those for
stages I and II.
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